Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Topline data from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes, have been announced.
The ACHIEVE-2 trial compared the efficacy and safety of orforglipron with dapagliflozin in adults with T2D and inadequate glycemic control with metformin. Participants (N=962) were randomly assigned to receive orforglipron (3mg, 12mg, or 36mg) or dapagliflozin (10mg) once daily, alongside background metformin therapy.
The primary endpoint was the change from baseline to week 40 in HbA1c, with a baseline HbA1c of 8.1%.
Author summary: Orforglipron lowers HbA1c significantly.
More News
- Illinois PIRG: State Farm's influence blocks regulators' probe
- High winds across parts of Colorado create fire danger Monday
- When the Outside World Feeds Fear, Student Peer Support Becomes a Lifeline
- Food Lion feeds gala apple bag campaign provides over 13.8 million meals
- Super funds just posted another solid year. Here’s what they’re leaving on the table
- Bird's eye view: U of T study uses aerial imagery to gauge health of city's green roofs
- Radiance Films Release Limited Editions of Harry Kümel's DAUGHTERS OF DARKNESS and MALPERTUIS | Horror Cult Films
- Amazon Deletes Prime Video Tweet Mocking Woman's Engagement Ring With 'The Summer I Turned Pretty' Meme
- Layoffs hit Colorado programs for substance abuse and mental health services
- The lion of Zion has awakened - Israel Today